shanghai pharma

Recent Articles

RELATED ARTICLES

  1. Hutchmed has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States.
    Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  2. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  3. Clinical trials come up short again for Alphamab Oncology
    9966.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Akeso marks profit milestone with swift rights issue
    9926.HK
  6. TransThera seeks Hong Kong IPO to sustain cancer drug research
  7. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva